Login to Your Account



Making Money from 'Great Science'

After a Rough 2011, Xoma Puts Ship on an Even Keel

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, December 10, 2012

Last year was rather rough for Xoma Corp. In March 2011, the company saw its interleukin-1 beta inhibitor gevokizumab miss its primary endpoint in a Phase IIb trial in Type II diabetes, eliminating the opportunity to enter the lucrative market. (See BioWorld Today, March 24, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription